Avant Brands Reports Record-Breaking Results in Fiscal Year 2023
KELOWNA, BC / ACCESSWIRE / February 29, 2024 / Avant Brands Inc (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer...
COVID-19
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value...
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality...
TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California
FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025SEATTLE and VANCOUVER, British Columbia, Feb....
Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases
First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D...
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds...
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue...
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative -FOSTER...
Early Pulmonary Fibrosis Detection Holds the Key to Better Health Outcomes for Canadians Living with COVID-19 and Rheumatoid Arthritis
Canadians who have had COVID-19, and other chronic diseases, are experiencing Pulmonary Fibrosis (PF) at significantly higher rates than others,...
Catheter Precision, Inc. (NYSE American:VTAK) Announces the First Use of VIVO With a Pediatric Patient in Turkey
FORT MILL, SC / ACCESSWIRE / February 28, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a U.S. based...
Moderna to Present at Upcoming Investor Conferences in March 2024
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional...
Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay
Springfield, Oregon--(Newsfile Corp. - February 27, 2024) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)...
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions...
Validic integrates Smart Meter cellular-enabled health devices into personalized care platform
DURHAM, N.C., Feb. 26, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, continues to expand...